Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
6,204 results
- EVARIndependent statistical analysis of Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04210180).
- EVarQuitIndependent statistical analysis of EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03262662).
- EVAS2Independent statistical analysis of EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity: Complete Statistical AnalysisIndependent statistical analysis of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex: Complete Statistical AnalysisIndependent statistical analysis of Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Everolimus for Cancer With TSC1 or TSC2 Mutation: Complete Statistical AnalysisIndependent statistical analysis of Everolimus for Cancer With TSC1 or TSC2 Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02201212).
- Everolimus for Children With Recurrent or Progressive Ependymoma: Complete Statistical AnalysisIndependent statistical analysis of Everolimus for Children With Recurrent or Progressive Ependymoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02155920).
- Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVERZOTAIndependent statistical analysis of Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVIDENCEIndependent statistical analysis of Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment: primary endpoint results, effect estimate with confidence interval,…
- EvidenceIndependent statistical analysis of Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVITAIndependent statistical analysis of Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EvKIndependent statistical analysis of Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EVOGUARDIndependent statistical analysis of Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVOKEIndependent statistical analysis of Safety and Efficacy Study of the Evoke™ SCS System With Feedback vs. Conventional Stimulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EVOLVE48Independent statistical analysis of A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EVOLVEIIIndependent statistical analysis of Epanova® for Lowering Very High Triglycerides II (EVOLVE II): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02009865).
- Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies: primary endpoint results, effect estimate with…
- Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EXAMINERIndependent statistical analysis of A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing: Complete Statistical AnalysisIndependent statistical analysis of Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT07074171).
- ExCeLIndependent statistical analysis of EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EXCELIndependent statistical analysis of Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Exercise for Swallowing Problems After Stroke: Complete Statistical AnalysisIndependent statistical analysis of Exercise for Swallowing Problems After Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00722111).
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload: Complete Statistical AnalysisIndependent statistical analysis of Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.: Complete Statistical AnalysisIndependent statistical analysis of Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.: primary endpoint results,…
- Exparel vs. Standard Bupivicaine for Abdominoplasty: Complete Statistical AnalysisIndependent statistical analysis of Exparel vs. Standard Bupivicaine for Abdominoplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01853176).
- ExpeditionPROIndependent statistical analysis of A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Exploration of Pupil Dilation in Horner’s Patients Taking Flomax: Complete Statistical AnalysisIndependent statistical analysis of Exploration of Pupil Dilation in Horner's Patients Taking Flomax: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03615508).
- Exploratory Study for Toivoa-001 on Human Factors: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study for Toivoa-001 on Human Factors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06477913).
- Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures: Complete Statistical AnalysisIndependent statistical analysis of Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures: primary endpoint results, effect estimate with…
- Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety: Complete Statistical AnalysisIndependent statistical analysis of Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00842946).
- ExRx in FAIndependent statistical analysis of NAD+ and Exercise in FA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04192136).
- EXTAXIndependent statistical analysis of Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Extended Dosing With Eltrombopag for Severe Aplastic Anemia: Complete Statistical AnalysisIndependent statistical analysis of Extended Dosing With Eltrombopag for Severe Aplastic Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01891994).
- Extending taVNS Paired With Infant CIMT Into a Home-Based Setting: Complete Statistical AnalysisIndependent statistical analysis of Extending taVNS Paired With Infant CIMT Into a Home-Based Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05857527).
- Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures: Complete Statistical AnalysisIndependent statistical analysis of Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Extension Study of MYL-1701P-3001 for Safety and Efficacy: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of MYL-1701P-3001 for Safety and Efficacy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04674800).
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection: primary endpoint results, effect estimate with confidence interval, sample-size…
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.: primary endpoint results, effect estimate with confidence interval,…
- Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects: Complete Statistical AnalysisIndependent statistical analysis of Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects: primary endpoint results, effect estimate…